Drug firm Strides Arcolab has received approval from the UShealth regulator to market a generic carboplatin injection for the treatment ofovarian cancer. Onco Therapies, a wholly-owned subsidiary of the company, hasreceived United States Food and Drug Administration (USFDA) approval forCarboplatin injections. The approval by the USFDAis for carboplatin injections in strengths of 10 mg/mL, packaged in 50 mg/5 mL,150 mg/15 mL, 450 mg/45 mL and 600 mg/60 mL multi-dose vials. Carboplatinis part of the oncology portfolio licensed to Pfizer in January, 2010, for theUS market and is expected to be launched shortly. Accordingto IMS data of June 11, the US market for generic carboplatin is worth nearly$35 million.
